source
- Intellia’s CRISPR therapy cuts hereditary angioedema attacks by 87% in Phase 3 trialIntellia Therapeutics reported that its experimental CRISPR-based drug lonvo-z met the primary endpoint in a Phase 3 study for hereditary angioedema, a rare swelling disorder. The trial showed an…
- Veradermics reports positive Phase 3 results for oral baldness pillVeradermics said its experimental oral formulation of minoxidil met the primary goal of its Phase 3 trial, showing significantly more new hair growth over six months compared with placebo. The dru…